SEC Form 4 · accession 0001654954-18-000107
ENDRA Life Sciences Inc. · NDRA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Anthony Digiandomenico
Director
Period of report
Jan 2, 2018
Accepted (ET)
Jan 4, 2018 · 5:22 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001681682
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionsF1 | $4.95 | Jan 2, 2018 | A | 6,061 | A | Jan 2, 2019 | Jan 2, 2026 | Common Stock | 6,061 | 6,061 | D |
Explanation of responses
- F1Represents a stock option award granted on January 2, 2018 pursuant to the Issuer's Non-Employee Director Compensation Policy.